Riskpilot← Back to searchSign inGet full accessUllman Medical AB
ABActiveOrg 5568900947Mårdvägen 52General medical practice activities · NACE 8621Est. 20120 employees
Revenue 2025
SEK 2,4M
-6% vs 2024
EBITDA margin
93.2%
-4% vs 2024
Equity ratio
88.9%
Financial strength
Net profit 2025
SEK 1,8M
-7% vs 2024
| Revenue | SEK 2,4M | -6% |
| EBITDA | SEK 2,2M | -4% |
| Net profit | SEK 1,8M | -7% |
| Total assets | SEK 5,4M | -5% |
| Equity | SEK 4,8M | +28% |
| Employees | 0 | — |
Legal name
Ullman Medical AB
Org number
5568900947
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
7 april 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva medicinsk konsultverksamhet och därmed förenlig verksamhet.
Address
Mårdvägen 52
Email
andreas.hagstrom@startabolaget.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 193 | 2 424 | 2 322 | 2 526 | 2 363 |
| Staff expenses | — | −0 | — | — | — |
| EBITDA | 2 075 | 2 279 | 2 165 | 2 290 | 2 201 |
| Depreciation & amort. | −1 | −5 | −6 | −5 | −5 |
| EBIT | 2 074 | 2 274 | 2 159 | 2 285 | 2 196 |
| Net financials | — | −1 | −7 | 94 | 22 |
| Profit before tax | 2 074 | 2 272 | 2 152 | 2 378 | 2 218 |
| Tax | −430 | −470 | −461 | −486 | −464 |
| Net profit | 1 644 | 1 802 | 1 692 | 1 892 | 1 754 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 320 | 4 295 | 5 327 | 5 699 | 5 392 |
| Equity | 1 711 | 2 113 | 3 365 | 3 757 | 4 796 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 1 609 | 2 182 | 1 963 | 1 943 | 596 |
| Total debt | 1 609 | 2 182 | 1 963 | 1 943 | 596 |
EBITDA margin
93.2%
This company
15.8%
Market median
+490% vs market
20212025
Equity ratio
88.9%
This company
38.2%
Market median
+133% vs market
20212025
Return on equity
36.6%
This company
18.4%
Market median
+99% vs market
20212025
Net profit margin
74.2%
This company
8.1%
Market median
+816% vs market
20212025
Asset turnover
0.44×
This company
1.12×
Market median
-61% vs market
20212025
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BE Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ullman Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bengt Erik Ullman | Chief Executive Officer | 0 companies |
| Eva Elisabeth Ullman | Deputy Board Member | 0 companies |